Key Highlights

  • PacBio shares are trading 22.24% higher at $3.00 on Wednesday, October 28, 2026, against an implied prior close of about $2.45 (calculated).
  • The 52-week range runs from $1.07 to $3.435, so the current price sits near the top of that band.
  • Second-quarter 2026 revenue was $39.0 million, and full-year 2026 revenue guidance stands at $155 million to $165 million.
  • Cash, cash equivalents and investments were $236.9 million at June 30, 2026, against $644.3 million of convertible senior notes.
  • Third-quarter 2026 results are scheduled for November 4, 2026.

PacBio Shares Jump: What Is Behind a 22.24% Move in a Penny Stock?

Pacific Biosciences of California (NASDAQ:PACB) shares are trading 22.24% higher at $3.00 on Wednesday, October 28, 2026, making the stock one of the most heavily traded names under $5. No dated company release accompanied the move, so the jump cannot be tied to a specific announcement.

PacBio designs and manufactures DNA sequencing systems, consumables and reagent kits built around its long-read SMRT technology. The company is based in Menlo Park, California, employs about 485 people and went public in October 2010.

Shares closed at $2.24 in an afternoon reading on Monday, October 26, 2026, when the market capitalization was $696.26 million. Today's price now sits above the roughly $2.54 average analyst target, a data point rather than a view on value.

PacBio Recent News Flow: Do the Verily and TychoBio Collaborations Matter?

On October 19, 2026, PacBio announced a multi-year collaboration with Verily Health to pair its HiFi sequencing with Verily's cloud and AI data platform. On October 6, it said it would work with TychoBio to generate full-length RNA data for training AI models aimed at rare disease therapies.

A research firm, Stephens, raised its price target from $1.50 to $2.50 on October 23 and kept an Overweight rating. Another firm, UBS, assumed coverage in late August with a Neutral rating and a $1.35 target.

The stock has traded between $1.07 and $3.435 over 52 weeks, so a move to $3.00 puts shares close to the top of that range.

PacBio Second-Quarter Numbers: How Heavy Is the Burn Against $644.3 Million of Convertible Notes?

PacBio reported second-quarter revenue of $39.0 million on August 5, 2026, down from $39.8 million a year earlier. Consumables revenue rose to $20.1 million from $18.9 million, while instrument revenue slipped to $12.8 million from $14.2 million.

The company placed 20 Revio systems, up from 15, and 26 Vega systems, down from 38. Annualized Revio pull-through was about $202,000 per system, compared with about $219,000 a year earlier.

GAAP gross margin was 32%, versus 37%, and non-GAAP gross margin was 36%. The GAAP net loss was $44.74 million, or $0.14 per share, and the non-GAAP net loss was $41.95 million.

Cash, cash equivalents and investments were $236.9 million at June 30, 2026, down from $279.5 million at December 31, 2025. Convertible senior notes were $644.3 million, and stockholders' equity was a deficit of $33.2 million.

Management cut full-year 2026 revenue guidance to $155 million to $165 million, began the global rollout of SPRQ-Nx chemistry priced at $345 per genome, and announced restructuring steps and a new chief executive on the same day.

What to Watch Next: Does the November 4 Report Explain Today's Rally?

PacBio said on October 15, 2026, that it will report third-quarter results on November 4, 2026. The market is looking at the guidance range, instrument placements, and cash use. Short-interest data show 47.22 million shares sold short, or 15.53% of the float, with 4.51 days to cover, a setup that can magnify moves in either direction when volume is heavy.